CT Joins $90 Million Settlement with GlaxoSmithKline

The state will receive $1.6 million as part of a $90 million multi-state settlement with the drug maker GlaxoSmithKline to resolve allegations that the company unlawfully promoted its diabetes drug, Avandia. Thirty-seven other states are participating in the settlement, following claims that GlaxoSmithKline (GSK) engaged in unfair and deceptive practices by misrepresenting Avandia’s potential cardiovascular risks and by promoting the drug to physicians and other healthcare professionals with false and misleading representations about Avandia’s safety profile. The settlement resolves the state’s claim against the company under the Connecticut Unfair Trade Practices Act. Connecticut’s share of the settlement is $1,668,482, of which $100,000 will be allocated to the Department of Consumer Protection to support the Prescription Drug Monitoring Program and the agency’s Consumer Fund. Another $100,000 will go to the Attorney General’s Consumer Fund.

More about: , , , ,